Market Access News | pharmaphorum

News

FDA elevates chief scientist Bumpus to the number two role

FDA chief scientist Namandjé Bumpus has been named as principal deputy commissioner, replacing long-serving Janet Woodcock when she steps down early next year.

News

Astellas builds case for menopause drug fezolinetant

New data for Astellas Pharma’s non-hormonal menopause therapy fezolinetant has shown it remains effective to 24 weeks, consolidating the evidence of the drug as it starts

News

FDA kicks off review of Karuna’s schizophrenia drug KarXT

Karuna Therapeutics said this morning that the FDA has formally started its review of KarXT, aiming to become the first drug to reach the market for schizophrenia with a n

News

CSL, Arcturus get first approval for self-assembling RNA jab

Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater effi

News

FDA okays first therapy for desmoid tumours from SpringWorks

Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non

News

Lifeline for Wolman disease kids as NICE backs Alexion drug

Infants with a rare and fatal congenital disorder called Wolman disease in England and Wales will soon have access to a new drug via the NHS that can dramatically extend t

FDA elevates chief scientist Bumpus to the number two role

Astellas builds case for menopause drug fezolinetant

FDA kicks off review of Karuna’s schizophrenia drug KarXT

CSL, Arcturus get first approval for self-assembling RNA jab

FDA okays first therapy for desmoid tumours from SpringWorks

Lifeline for Wolman disease kids as NICE backs Alexion drug

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks